Sunday - August 2, 2026
Exdensur Approved in Japan for Severe Asthma and Chronic Rhinosinusitis With Nasal Polyps
January 06, 2026
LONDON, England, Jan. 6 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Jan. 5, 2025:

* * *

Exdensur (depemokimab) approved in Japan for severe asthma and chronic rhinosinusitis with nasal polyps

* Exdensur is the first and only ultra-long-acting biologic in Japan for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP)

* Approval based on data from the SWIFT . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products

Click here for more information about our products